HLTRF News and Press, HLS Therapeutics Inc

2024-05-09 12:46:13 ET More on HLS Therapeutics Historical earnings data for HLS Therapeutics Financial information for HLS Therapeutics Read the full article on Seeking Alpha For further details see: HLS Therapeutics EPS of -$0.19 beats by $0.04, revenue...

2024-03-14 12:28:08 ET More on HLS Therapeutics Historical earnings data for HLS Therapeutics Financial information for HLS Therapeutics Read the full article on Seeking Alpha For further details see: HLS Therapeutics GAAP EPS of -$0.17 misses by $0.04, r...

2023-12-18 07:22:03 ET More on HLS Therapeutics: Historical earnings data for HLS Therapeutics Financial information for HLS Therapeutics For further details see: HLS Therapeutics appoints John Hanna as interim CFO

2023-08-10 11:58:44 ET HLS Therapeutics press release ( TSX: HLS:CA ): Q2 GAAP EPS of -$0.29. Revenue of $16.4M (+5.8% Y/Y). New leadership with the appointment of Craig Millian as CEO and Brian Walsh as Senior Vice President, Commercial; and a redu...

2023-05-11 13:11:19 ET HLS Therapeutics press release ( OTCPK:HLTRF ): Q1 GAAP EPS of -$0.18. Revenue of $14.8M (+1.4% Y/Y) misses by $1.24M . VASCEPA 2023 OUTLOOK The Company expects revenue growth for Vascepa to increase over the course of the year. The positiv...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

2023-03-16 08:54:54 ET HLS Therapeutics press release ( OTCPK:HLTRF ): Q4 GAAP EPS of -$0.20. Revenue of $15.68M (-0.1% Y/Y). For further details see: HLS Therapeutics GAAP EPS of -$0.20, revenue of $15.68M

HLS Therapeutics press release ( OTCPK:HLTRF ): Q3 GAAP EPS of -$0.14. Revenue of $15.7M (+4.0% Y/Y). Cash and cash equivalents was $21.3 million at September 30, 2022 compared to $21.2 million at December 31, 2021 For further details see: HLS Therapeutics GAAP E...

HLS Therapeutics press release ( OTCPK:HLTRF ): Q2 GAAP EPS of -$0.28 (vs. -$0.07 Y/Y). Revenue of $15.53M (+3.9% Y/Y) misses by $1.27M . For further details see: HLS Therapeutics Q2 GAAP loss per share widens, revenue misses

The following slide deck was published by HLS Therapeutics Inc. in conjunction with their 2022 Q1 earnings call. For further details see: HLS Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation